866-997-4948(US-Canada Toll Free)

Dengue Fever - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 195 Pages

Dengue Fever - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever Pipeline Review, H2 2016, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.

Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5, 32 and 16 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 2, 6, 10 and 15 molecules, respectively.

Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 5
Dengue Fever Overview 6
Therapeutics Development 7
Dengue Fever - Therapeutics under Development by Companies 9
Dengue Fever - Therapeutics under Investigation by Universities/Institutes 12
Dengue Fever - Pipeline Products Glance 14
Dengue Fever - Products under Development by Companies 17
Dengue Fever - Products under Investigation by Universities/Institutes 20
Dengue Fever - Companies Involved in Therapeutics Development 22
Dengue Fever - Therapeutics Assessment 59
Drug Profiles 68
Dengue Fever - Dormant Projects 164
Dengue Fever - Discontinued Products 170
Dengue Fever - Product Development Milestones 171
Appendix 184

List of Tables
Number of Products under Development for Dengue Fever, H2 2016 17
Number of Products under Development for Dengue Fever - Comparative Analysis, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Development by Companies, H2 2016 (Contd..1) 20
Number of Products under Development by Companies, H2 2016 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 23
Comparative Analysis by Late Stage Development, H2 2016 24
Comparative Analysis by Clinical Stage Development, H2 2016 25
Comparative Analysis by Early Stage Development, H2 2016 26
Products under Development by Companies, H2 2016 27
Products under Development by Companies, H2 2016 (Contd..1) 28
Products under Development by Companies, H2 2016 (Contd..2) 29
Products under Investigation by Universities/Institutes, H2 2016 30
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 31
Dengue Fever - Pipeline by Abivax SA, H2 2016 32
Dengue Fever - Pipeline by Agilvax Inc, H2 2016 33
Dengue Fever - Pipeline by Altravax Inc, H2 2016 34
Dengue Fever - Pipeline by Biological Mimetics Inc, H2 2016 35
Dengue Fever - Pipeline by Bioneer Corp, H2 2016 36
Dengue Fever - Pipeline by Biotron Ltd, H2 2016 37
Dengue Fever - Pipeline by Codagenix Inc, H2 2016 38
Dengue Fever - Pipeline by Emergent BioSolutions Inc, H2 2016 39
Dengue Fever - Pipeline by Ennaid Therapeutics LLC, H2 2016 40
Dengue Fever - Pipeline by GeneSegues Inc, H2 2016 41
Dengue Fever - Pipeline by GlaxoSmithKline Plc, H2 2016 42
Dengue Fever - Pipeline by Globavir Biosciences Inc, H2 2016 43
Dengue Fever - Pipeline by Hawaii Biotech Inc, H2 2016 44
Dengue Fever - Pipeline by HSRx Group, H2 2016 45
Dengue Fever - Pipeline by Humabs BioMed SA, H2 2016 46
Dengue Fever - Pipeline by Immunotope Inc, H2 2016 47
Dengue Fever - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 48
Dengue Fever - Pipeline by Johnson & Johnson, H2 2016 49
Dengue Fever - Pipeline by Kineta Inc, H2 2016 50
Dengue Fever - Pipeline by Merck & Co Inc, H2 2016 51
Dengue Fever - Pipeline by Molplex Ltd, H2 2016 52
Dengue Fever - Pipeline by NanoViricides Inc, H2 2016 53
Dengue Fever - Pipeline by Novartis AG, H2 2016 54
Dengue Fever - Pipeline by NovaTarg Therapeutics Inc, H2 2016 55
Dengue Fever - Pipeline by Panacea Biotec Ltd, H2 2016 56
Dengue Fever - Pipeline by Plex Pharmaceuticals Inc, H2 2016 57
Dengue Fever - Pipeline by ProtInhi BV, H2 2016 58
Dengue Fever - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 59
Dengue Fever - Pipeline by Sarepta Therapeutics Inc, H2 2016 60
Dengue Fever - Pipeline by SIGA Technologies Inc, H2 2016 61
Dengue Fever - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 62
Dengue Fever - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 63
Dengue Fever - Pipeline by TechnoVax Inc, H2 2016 64
Dengue Fever - Pipeline by Themis Bioscience GmbH, H2 2016 65
Dengue Fever - Pipeline by VaxInnate Corp, H2 2016 66
Dengue Fever - Pipeline by Visterra Inc, H2 2016 67
Dengue Fever - Pipeline by VLP Therapeutics LLC, H2 2016 68
Assessment by Monotherapy Products, H2 2016 69
Number of Products by Stage and Target, H2 2016 71
Number of Products by Stage and Mechanism of Action, H2 2016 73
Number of Products by Stage and Route of Administration, H2 2016 75
Number of Products by Stage and Molecule Type, H2 2016 77
Dengue Fever - Dormant Projects, H2 2016 174
Dengue Fever - Dormant Projects (Contd..1), H2 2016 175
Dengue Fever - Dormant Projects (Contd..2), H2 2016 176
Dengue Fever - Dormant Projects (Contd..3), H2 2016 177
Dengue Fever - Dormant Projects (Contd..4), H2 2016 178
Dengue Fever - Dormant Projects (Contd..5), H2 2016 179
Dengue Fever - Discontinued Products, H2 2016 180

List of Figures
Number of Products under Development for Dengue Fever, H2 2016 17
Number of Products under Development for Dengue Fever - Comparative Analysis, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Late Stage Development, H2 2016 24
Comparative Analysis by Clinical Stage Development, H2 2016 25
Comparative Analysis by Early Stage Products, H2 2016 26
Assessment by Monotherapy Products, H2 2016 69
Number of Products by Top 10 Targets, H2 2016 70
Number of Products by Stage and Top 10 Targets, H2 2016 70
Number of Products by Top 10 Mechanism of Actions, H2 2016 72
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 72
Number of Products by Routes of Administration, H2 2016 74
Number of Products by Stage and Routes of Administration, H2 2016 74
Number of Products by Top 10 Molecule Types, H2 2016 76
Number of Products by Stage and Top 10 Molecule Types, H2 2016 76

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *